ASCO26: BMS and J&J Debut Shining Multiple Myeloma Data

Why It Matters

These data could shift multiple myeloma treatment toward more effective, earlier‑line regimens and expand outpatient options, accelerating regulatory approvals and reshaping market dynamics.

Key Takeaways

• MeziKd achieved 18‑month PFS vs 8.3 months with Kd
• ORR 80.2% for MeziKd, double the control arm
• Tecvayli cut progression risk by 71% in second‑line RRMM
• Tecvayli showed comparable safety to standard regimens
• Outpatient Tecvayli/Talvey regimens yielded ~70% overall response rates

Pulse Analysis

Multiple myeloma remains a therapeutic frontier, with patients often exhausting options after each relapse. The ASCO 2026 presentations from Bristol Myers Squibb and Johnson & Johnson underscore a new wave of targeted agents that promise deeper, more durable remissions. BMS’s MeziKd, a cereblon E3 ligase modulator paired with carfilzomib and dexamethasone, extended median PFS to 18 months and lifted overall response rates above 80%, marking a substantial gain over the standard Kd backbone. Such efficacy, especially in higher‑risk and later‑line cohorts, positions MeziKd as a strong candidate for expedited regulatory review.

Johnson & Johnson’s Tecvayli, a bispecific T‑cell engager, demonstrated a 71% reduction in disease progression risk and a 40% drop in mortality when introduced as early as second‑line therapy. The trial’s robust complete‑response rates and safety parity with conventional pomalidomide‑bortezomib‑dexamethasone or carfilzomib‑dexamethasone regimens suggest that Tecvayli could become a new standard for early‑relapse patients, offering a steroid‑sparing, outpatient‑friendly alternative. The data also signal broader acceptance of bispecific antibodies, potentially accelerating their integration into community oncology practices.

The investigator‑led outpatient study further validates the feasibility of delivering complex immunotherapies outside the infusion center. By employing step‑up dosing and prophylactic tocilizumab, both Tecvayli and Talvey achieved overall response rates near 70%, with manageable adverse‑event profiles. This shift toward outpatient administration could reduce hospital burden, improve patient quality of life, and expand market penetration for next‑generation myeloma agents. As regulators evaluate these findings, the industry may see a rapid expansion of label indications, heightened competition, and increased investment in bispecific and cereblon‑targeted platforms.